NCT04927585View on ClinicalTrials.gov

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 8, 2021

Primary Completion Date

December 7, 2023

Study Completion Date

December 7, 2023

Conditions
HIV Infections
Interventions
BIOLOGICAL

env (A,B,C,A/E)/gag (C) DNA Vaccine

Administered by intramuscular injection in the deltoid

BIOLOGICAL

gp120 (A,B,C,A/E) Protein Vaccine

Administered by intramuscular injection in the deltoid

BIOLOGICAL

GLA-SE adjuvant

Administered by intramuscular injection in the deltoid.

BIOLOGICAL

Placebo

Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Access to Advanced Health Institute (AAHI)

OTHER

lead

Worcester HIV Vaccine

INDUSTRY